<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03345797</url>
  </required_header>
  <id_info>
    <org_study_id>NAT-2017-01</org_study_id>
    <nct_id>NCT03345797</nct_id>
  </id_info>
  <brief_title>Evaluation of Testosterone Nasal Gel in Hypogonadal Boys</brief_title>
  <official_title>A Multicenter, Open Label, Variable Dose, Two Arm Pilot Paediatric Phase 1 PK Study to Evaluate Testosterone Nasal Gel (4.5% w/w) in Hypogonadal Boys</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acerus Biopharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acerus Pharmaceuticals Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      PK study to evaluate serum levels of testosterone post nasal delivery in two cohorts of
      hypogonadal boys.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ARM 1 - 10 prepubertal, 12-17 years old boys with no prior exposure to TRT will receive
      single dose of 5.5 mg on day one and single dose of 11 mg on day 2 with repeat blood draws to
      assess serum levels of testosterone and metabolites.

      ARM 2 - 10 Tanner Stage 3, 12-17 years old boys on TRT with bone age &gt;= 13 years will receive
      single dose of 11 mg on day one, and single dose of 11 mg in the morning and a second 11 mg
      dose in the afternoon on day 2 with repeat blood draws to assess serum levels of testosterone
      and metabolites.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 1, 2018</start_date>
  <completion_date type="Anticipated">November 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 30, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>dual arm: naïve vs TRT experienced</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax)</measure>
    <time_frame>48 hours (approx)</time_frame>
    <description>Cmax for serum testosterone, serum DHT and serum estradiol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC)</measure>
    <time_frame>48 hours (approx)</time_frame>
    <description>AUC for serum testosterone, serum DHT and serum estradiol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Minimum serum concentration (Cmin)</measure>
    <time_frame>48 hours (approx)</time_frame>
    <description>Cmin for serum testosterone, serum DHT and serum estradiol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach maximum plasma concentration (tmax)</measure>
    <time_frame>48 hours (approx)</time_frame>
    <description>tmax for serum testosterone, serum DHT and serum estradiol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Safety)</measure>
    <time_frame>5 days</time_frame>
    <description>Safety assessments will include adverse events, clinical laboratory measurements of serum testosterone, DHT and estradiol levels, and vital sign measurements. A phone call will be made 3 days after the patient leaves the clinic to collect any SAEs or AEs that may occur.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events (Tolerability)</measure>
    <time_frame>48 hours (approx)</time_frame>
    <description>To include a adverse events that relate to tolerability and a patient and healthcare provider questionnaire on ease of use dispenser and gel administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Hypogonadism</condition>
  <arm_group>
    <arm_group_label>Naive patients - ARM 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRT naïve subjects, Tanner Stage of 0, receiving Testosterone Nasal Gel [Natesto] - Single dose of 5.5 mg Natesto on Day 1 and a single dose of 11 mg Natesto on Day 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-naive patients - ARM 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TRT non-naïve subjects (have had prior testosterone treatment), Tanner Stage &gt;/= 3, receiving Testosterone Nasal Gel [Natesto] - Single dose of 11 mg Natesto on Day 1. On Day 2, 11 mg dose of Natesto in the morning and 11 mg dose of Natesto 12 hours later</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Testosterone Nasal Gel [Natesto]</intervention_name>
    <description>nasal gel containing 4.5% w/w testosterone</description>
    <arm_group_label>Naive patients - ARM 1</arm_group_label>
    <arm_group_label>Non-naive patients - ARM 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        ARM 1 (naïve patients): Participants who meet all of the following inclusion criteria will
        be eligible for participation in the study:

          1. Hypogonadal boys;

          2. Chronological age 12 to &lt;18 years;

          3. No prior exposure to TRT;

          4. Prepubertal

          5. Parent/guardian and patient able to understand and provide signed informed consent;

        ARM 2 (non-naïve patients): Participants who meet all of the following inclusion criteria
        will be eligible for participation in the study:

          1. Hypogonadal boys with a bone age of ≥13 years (a historical value within the last 12
             months will be acceptable);

          2. Chronological age 12 to &lt;18 years;

          3. Taking an existing TRT treatment dose;

          4. Tanner Stage ≥3

          5. Parent/guardian and patient able to understand and provide signed informed consent;

        Exclusion Criteria:

        ARM 1 (naïve patients) AND ARM 2 (non-naïve patients): Participants who meet any of the
        following criteria will be excluded from participation in the study:

          1. Any active allergic condition or presentation of symptoms including allergic rhinitis;

          2. An upper respiratory tract infection;

          3. Use of any form of intranasal medication delivery other than periodic short-term (less
             than 3 days) use of sympathomimetic decongestants, within the last 3 months;

          4. In the opinion of the Investigator, significant intercurrent disease of any type, in
             particular liver, kidney, heart disease, stroke, or psychiatric illness;

          5. History of pituitary or hypothalamic tumors or history of any malignancy excluding
             basal cell or squamous cell carcinoma of the skin curatively treated by surgery;

          6. History of nasal disorders, nasal or sinus surgery, nasal fracture within the previous
             6 months or nasal fracture that caused a deviated anterior nasal septum surgery,
             mucosal inflammatory disorders, specifically Sjogren's syndrome;

          7. History of severe adverse drug reactions to testosterone therapies;

          8. Current treatment with other androgens (e.g., dehydroepiandrosterone [DHEA]), anabolic
             steroids, or other sex hormones;

          9. Treatment with estrogens, gonadotropin-releasing hormone (GnRH) agonists, or growth
             hormone within the previous 12 months;

         10. Treatment with drugs that interfere with the metabolism of testosterone, such as
             anastrozole, clomiphene, dutasteride, finasteride, flutamide, ketoconazole,
             spironolactone, or testolactone;

         11. Diabetes mellitus;

         12. Participation in any other research study during the conduct of this study or 30 days
             prior to the initiation of this study.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>hypogonadal boys</gender_description>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Syed Faisal Ahmed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Hospital for Children, U. of Glasgow</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Matthew Gronski, Ph.D.</last_name>
    <phone>289-334-1461</phone>
    <email>mgronski@aceruspharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nathan Bryson, Ph.D.</last_name>
    <phone>416-679-0776</phone>
    <email>nbryson@aceruspharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Glasgow, Royal Hospital for Children</name>
      <address>
        <city>Glasgow</city>
        <state>Scotland</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Faisal S Ahmed, MD</last_name>
      <phone>+44 141 451 5841</phone>
      <email>Faisal.Ahmed@glasgow.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Faisal S Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cambridge University Hospital's NHS Foundation Trust</name>
      <address>
        <city>Cambridge</city>
        <zip>CB2 0QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlo Acerini, MD</last_name>
      <phone>+44 1223 336865</phone>
      <email>cla22@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>Carlo L Acerini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alder Hey Children's Hospital</name>
      <address>
        <city>Liverpool</city>
        <zip>L14 5AB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dan Hawcutt</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>October 10, 2017</study_first_submitted>
  <study_first_submitted_qc>November 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>July 2, 2019</last_update_submitted>
  <last_update_submitted_qc>July 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Paediatric</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypogonadism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

